FDA approves ULTOMIRIS® for treatment of rare blood disorder

Retrieved on: 2021-06-08 16:18:45

Tags for this article:

Life Sciences

Biotechnology

Health care

Orphan drugs

Alexion Pharmaceuticals

AstraZeneca

Ravulizumab

Paroxysmal nocturnal hemoglobinuria

PNH

Food and Drug Administration

Eculizumab

David L. Hallal

Alexion Pharmaceuticals Inc.

Click the tags to see associated articles and topics

FDA approves ULTOMIRIS® for treatment of rare blood disorder. View article details on HISWAI: https://www.contemporarypediatrics.com/view/fda-approves-ultomiris-for-treatment-of-rare-blood-disorder

Excerpt

Alexion Pharmaceuticals, Inc. will make the drug immediately available for pediatric patients. Reference. 1. Alexion Pharmaceuticals. Alexion announces ...

Article found on: www.contemporarypediatrics.com

View Original Article